跳至主要内容
临床试验/NCT02631317
NCT02631317已完成不适用

Hospital Processes Reengineering of Intravenous Thrombolysis in Acute Ischemic Stroke in China

First Affiliated Hospital of Jinan University0 个研究点目标入组 2,178 人开始时间: 2014年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
2,178
主要终点
The rate of DNT less than 60 min within the patients treated with rt-PA

研究概览

简要总结

PROMISE is a prospective, nationwide, multicenter, longitudinal cohort study, focusing on hospital intravenous thrombolysis process reengineering for acute ischemic stroke (AIS). With a proposed "Reengineered Process Framework" for intravenous thrombolysis process by the PROMISE study steering committee, about 30 medical centers enters would be recruited nationwide, and each center would include consecutive AIS patients with an onset-to-door time (ODT) of less than 3.5 h. The investigators hypothesize that the proposed "Reengineered Process Framework" is suitable and feasible for hospitals in mainland of China; the rate of intravenous rt-PA thrombolysis in ischemic stroke patients with an ODT of less than 3.5 h would be more than 20% or be increased by 40% as compared with baseline; the proportion of patients with a door-to-needle (DNT) time of less than 60 min would be more than 20%, or be with an increase by ≥ 40% as compared with baseline.

详细描述

  1. After reviewing domestic and international clinical research literature, the PROMISE study steering committee constructed the "Reengineered Process Framework" for intravenous thrombolysis process with business process reengineering theory. The suggested "Reengineered Process Framework" is regarded as feasible and suitable for hospitals in mainland of China.
  2. The study period is 12 months, of which the first 3 months is the baseline period. After 3 months, all centers should develop new thrombolytic processes according to the "Reengineered Process Framework". The new processes are gradually implemented since the 4th month with continues care quality improvements.
  3. The "Reengineered Process Framework" adopts a form of comprehensive package, proposes unified key points of process reengineering, provides a series of supporting, standardized tools for process management, and establishes a real-time key performance indicator (KPI) monitoring feedback system, etc.
  4. Supporting, standardized tools includes: rapid identification tools of suspected stroke for medical personnel in the emergency system; stroke team building programs; real-time feedback form of KPI; standardized thrombolysis informed consent form and informed conversation public service advertising posters; suggested indications and contraindications for intravenous thrombolysis; standard operation procedure of intravenous rt-PA thrombolysis, etc.

With these methods, it is expected to raise the thrombolytic rate for patients arrived at medical center within 3.5 hours after the onset, and to shorten the door to needle time in China.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •All AIS patients with an onset-to-door time of less than 3.5 h of onset; informed consent

排除标准

  • •Complete remission of symptoms and signs, in consideration for patients with transient ischemic attack;
  • •Silent cerebral infarction without symptoms or signs;

结局指标

主要结局

The rate of DNT less than 60 min within the patients treated with rt-PA

时间窗: within 4.5 hours

The rate of patients with a door-to-needle (DNT) time of less than 60 min for intravenous rt-PA thrombolysis: ≥20%, with an increase over the baseline ≥ 40%

The thrombolysis rate of patients treated with rt-PA

时间窗: within 4.5 hours

The rate of intravenous rt-PA thrombolysis in ischemic stroke patients with an ODT of less than 3.5 h: ≥ 20%, with an increase over the baseline ≥ 40%

次要结局

  • death or dependence at 3-month(90 days)
  • intravenous rt-PA thrombolysis with an ODT of less than 2 h(3 hours)
  • favorable outcome at 3-month(90 days)

研究者

发起方
First Affiliated Hospital of Jinan University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Anding Xu

Professor

First Affiliated Hospital of Jinan University

相似试验